These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37579419)

  • 1. The Fentanyl System Shock - Are There Lessons to Learn From the COVID-19 System Shock Framework? Comment on "The COVID-19 System Shock Framework: Capturing Health System Innovation During the COVID-19 Pandemic".
    Meyer M; Westenberg JN; Krausz RM
    Int J Health Policy Manag; 2023; 12():7409. PubMed ID: 37579419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The COVID-19 System Shock Framework: Capturing Health System Innovation During the COVID-19 Pandemic.
    Hodgins M; van Leeuwen D; Braithwaite J; Hanefeld J; Wolfe I; Lau C; Dickins E; McSweeney J; McCaskill M; Lingam R
    Int J Health Policy Manag; 2022 Oct; 11(10):2155-2165. PubMed ID: 34814662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responding to a surge in overdose deaths: perspectives from US syringe services programs.
    Frost MC; Austin EJ; Corcorran MA; Briggs ES; Behrends CN; Juarez AM; Frank ND; Healy E; Prohaska SM; LaKosky PA; Kapadia SN; Perlman DC; Schackman BR; Des Jarlais DC; Williams EC; Glick SN
    Harm Reduct J; 2022 Jul; 19(1):79. PubMed ID: 35854351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of the COVID-19 Pandemic on Drug Use Behaviors, Fentanyl Exposure, and Harm Reduction Service Support among People Who Use Drugs in Rural Settings.
    Bolinski RS; Walters S; Salisbury-Afshar E; Ouellet LJ; Jenkins WD; Almirol E; Van Ham B; Fletcher S; Johnson C; Schneider JA; Ompad D; Pho MT
    Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tackling the overdose crisis: The role of safe supply.
    Ivsins A; Boyd J; Beletsky L; McNeil R
    Int J Drug Policy; 2020 Jun; 80():102769. PubMed ID: 32446183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study.
    Irvine MA; Oller D; Boggis J; Bishop B; Coombs D; Wheeler E; Doe-Simkins M; Walley AY; Marshall BDL; Bratberg J; Green TC
    Lancet Public Health; 2022 Mar; 7(3):e210-e218. PubMed ID: 35151372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceptability of a Fentanyl Vaccine to Prevent Opioid Overdose and Need for Personalized Decision-Making.
    Weitzman ER; Kossowsky J; Blakemore LM; Cox R; Dowling DJ; Levy O; Needles EW; Levy S
    Clin Infect Dis; 2022 Aug; 75(Suppl 1):S98-S109. PubMed ID: 35579508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heroin and fentanyl overdose deaths among cases age 50+ in the National Poison Data System, 2015-2020.
    Choi NG; Choi BY; DiNitto DM; Marti CN; Baker SD
    Clin Toxicol (Phila); 2022 May; 60(5):639-646. PubMed ID: 34985395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Psychoactive Substances and receding COVID-19 pandemic: really going back to "normal"?
    Napoletano S; Basile G; Lo Faro AF; Negro F
    Acta Biomed; 2022 May; 93(2):e2022186. PubMed ID: 35545997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the COVID-19 pandemic on opioid overdose and other adverse events in the USA and Canada: a systematic review.
    Simha S; Ahmed Y; Brummett CM; Waljee JF; Englesbe MJ; Bicket MC
    Reg Anesth Pain Med; 2023 Jan; 48(1):37-43. PubMed ID: 36202619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in characteristics of drug overdose death trends during the COVID-19 pandemic.
    DiGennaro C; Garcia GP; Stringfellow EJ; Wakeman S; Jalali MS
    Int J Drug Policy; 2021 Dec; 98():103392. PubMed ID: 34325184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid overdose decedent characteristics during COVID-19.
    Garcia GP; Stringfellow EJ; DiGennaro C; Poellinger N; Wood J; Wakeman S; Jalali MS
    Ann Med; 2022 Dec; 54(1):1081-1088. PubMed ID: 35467475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone.
    Kline A; Williams JM; Steinberg ML; Mattern D; Chesin M; Borys S; Chaguturu V
    J Subst Use Addict Treat; 2023 Jun; 149():209028. PubMed ID: 37003539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Profiling of Antifentanyl Monoclonal Antibodies in Combination with Naloxone in Pre- and Postexposure Models of Fentanyl Toxicity.
    Baehr CA; Wu MM; Pandit SG; Arias-Umana J; AuCoin D; Pravetoni M
    J Pharmacol Exp Ther; 2022 May; 381(2):129-136. PubMed ID: 35153198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study.
    Irvine MA; Buxton JA; Otterstatter M; Balshaw R; Gustafson R; Tyndall M; Kendall P; Kerr T; Gilbert M; Coombs D
    Lancet Public Health; 2018 May; 3(5):e218-e225. PubMed ID: 29678561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing traceable opioid material
    Mojica MA; Carter MD; Isenberg SL; Pirkle JL; Hamelin EI; Shaner RL; Seymour C; Sheppard CI; Baldwin GT; Johnson RC
    Toxicol Lett; 2019 Dec; 317():53-58. PubMed ID: 31560942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dawn of a new synthetic opioid era: the need for innovative interventions.
    Pardo B; Taylor J; Caulkins J; Reuter P; Kilmer B
    Addiction; 2021 Jun; 116(6):1304-1312. PubMed ID: 32869394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The COVID-19 pandemic and the health of people who use illicit opioids in New York City, the first 12 months.
    Bennett AS; Townsend T; Elliott L
    Int J Drug Policy; 2022 Mar; 101():103554. PubMed ID: 34911010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic.
    Fairbairn N; Coffin PO; Walley AY
    Int J Drug Policy; 2017 Aug; 46():172-179. PubMed ID: 28687187
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.